MedTrace Logo

Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）

NCT02189603 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 601

Last updated 2018-08-17

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and immunogenicity of the recombinant hepatitis E vaccine in people older than 65 years, and evaluate the efficacy of hepatitis E vaccine in this population.

Conditions

  • Hepatitis E

Interventions

BIOLOGICAL

Recombinant (E. Coli) Hepatitis E Vaccine

Sponsors & Collaborators

  • Xiamen Innovax Biotech Co., Ltd

    collaborator INDUSTRY

  • Xiamen Center for Disease Control and Prevention

    collaborator UNKNOWN

  • Jun Zhang

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-12-07
Completion
2015-12-07

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189603 on ClinicalTrials.gov